Adagene Inc (NASDAQ:ADAG) — Market Cap & Net Worth
Market Cap & Net Worth: Adagene Inc (ADAG)
Adagene Inc (NASDAQ:ADAG) has a market capitalization of $222.66 Million ($222.66 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16241 globally and #3863 in its home market, demonstrating a 3.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Adagene Inc's stock price $3.37 by its total outstanding shares 66072594 (66.07 Million). Also see total assets of Adagene Inc for a full breakdown of the balance sheet.
Adagene Inc Market Cap History: 2021 to 2026
Adagene Inc's market capitalization history from 2021 to 2026. Data shows change from $533.07 Million to $222.66 Million (-32.29% CAGR). Also see Adagene Inc (ADAG) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Adagene Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.01% | #445 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1598 of 3165 |
Weight: Adagene Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Adagene Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Adagene Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Adagene Inc stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
16.28x
Adagene Inc's market cap is 16.28 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $533.07 Million | $10.18 Million | -$73.18 Million | 52.39x | N/A |
| 2022 | $87.55 Million | $9.29 Million | -$79.97 Million | 9.42x | N/A |
| 2023 | $127.59 Million | $18.11 Million | -$18.95 Million | 7.04x | N/A |
| 2024 | $131.48 Million | $103.20K | -$33.42 Million | 1274.02x | N/A |
| 2025 | $124.88 Million | $7.67 Million | -$17.61 Million | 16.28x | N/A |
Competitor Companies of ADAG by Market Capitalization
Companies near Adagene Inc in the global market cap rankings as of September 18, 2026. Review ADAG tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Adagene Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Adagene Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Adagene Inc's market cap moved from $533.07 Million to $ 222.66 Million, with a yearly change of -32.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $222.66 Million | +78.31% |
| 2025 | $124.88 Million | -5.03% |
| 2024 | $131.48 Million | +3.06% |
| 2023 | $127.59 Million | +45.74% |
| 2022 | $87.55 Million | -83.58% |
| 2021 | $533.07 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Adagene Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $222.66 Million USD |
| MoneyControl | $222.66 Million USD |
| MarketWatch | $222.66 Million USD |
| marketcap.company | $222.66 Million USD |
| Reuters | $222.66 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Adagene Inc
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 anti… Read more